(Adnkronos) - “Il lupus eritematoso sistemico è una malattia autoimmune sistemica che può colpire tutti gli organi e apparati del nostro organismo in varai combinazione. Di qui la difficoltà nella diagnosi e nel trattamento. Negli ultimi 10 anni è cambiato il paradigma terapeutico di questa malattia, che permette di raggiungere la remissione e di spegnere una delle sue complicanze quale la nefrite lupica. E di ridurre al minimo e anche sospendere il cortisone. In particolare i Jak inibitori, famiglia di nuovi farmaci già disponibili in Italia da dicembre 2017 per l’artrite reumatoide”.
Category
🗞
NewsTranscript
00:00The systemic erythematous lupus is an autoimmune disease, as the name suggests.
00:11It is a disease that can affect all the organs of our body in various combinations.
00:17It is an extremely heterogeneous disease with a combination of symptoms and organ commitment that is extremely variable.
00:25It is difficult to find two cases of lupus that are superimposable, identical.
00:30Hence the initial difficulty in diagnosis, but sometimes also the difficulty in the treatment of this disease.
00:36In the last ten years, the therapeutic paradigm of this disease has changed,
00:41further changed because new biological and non-biological drugs have been made available to clinicians
00:47that allow the remission, that is, the absence of signs and symptoms of the disease,
00:53in a much higher percentage of patients.
00:56They then allow to eliminate one of the complications of the disease, such as lupus nephritis,
01:02in an even higher percentage and more quickly in patients with this complication.
01:08And they are drugs that also allow us to reduce, at least, and also suspend cortisone,
01:15what has been cardiotherapy for decades and that today we know is very useful in the initial stages,
01:21but in the long term itself can bring problems to the patient himself.
01:26Jack inhibitors are a family of new drugs that arrived at our disposal in Italy
01:32at the end of 2017, beginning of 2018, for the therapy of rheumatoid arthritis.
01:38They are new drugs because, unlike the biological drugs used always for this disease,
01:44rheumatoid arthritis, which are drugs that are injected in the vein or under the skin,
01:48the jack inhibitors are small molecules, that is, they are taken by mouth,
01:52therefore much more comfortable, with a power in rheumatoid arthritis,
01:55an effectiveness at least similar to biological, in such cases even superior.
01:59Recently, some of these jack inhibitors, at least two, are under experimentation
02:06in the systemic erythematous lupus, in the most advanced phase of experimentation.
02:11We participate in both these studies, which are multicentric and international,
02:16that is, they collect patients from all over the world, in practice,
02:19because they need very high numbers of patients treated with the drug,
02:26with the placebo, to verify the differences between one and the other of the two groups
02:32and to show that the drug is effective, as the previous studies have shown,
02:36those of phase 2, not those of registration, the initial ones.
02:39That is, the initial studies are very promising.
02:42We hope that these last, more extensive and so-called registration studies
02:47will confirm the effectiveness of the jack inhibitors,
02:50and therefore this use in clinical practice.